Peptology.
ANALYTICAL SERVICES

Certificate of Analysis

THIRD-PARTY PEPTIDE ANALYSIS · CARMONA, CAVITE, PHILIPPINES

PEP-COA-2026-SPEC-0001

✓ All ordered tests reported. All specified criteria met. Verify at peptology.ph/verify

TESTED FOR

CLIENT OF RECORD
Specimen Client Incorporated
Account PEP-C-0000 · Metro Manila, Philippines

CERTIFICATE ISSUED UNDER BRAND
Specimen Brand
Brand profile 1 of 5 available for this lot

PRODUCT & SAMPLE INFORMATION

MATERIAL	Retatrutide	DATE RECEIVED	20 July 2026
LABELLED AS	RT30	DATE TESTED	22 July 2026
LOT / BATCH NO.	SPEC-2026-0001	DATE ISSUED	23 July 2026
PEPTOLOGY SAMPLE ID	PEP-S-0000000001	TEST PACKAGE	P2 · Full QC
LABELLED CONTENT	30 mg per vial	VIALS SUBMITTED	3 · two analysed
DECLARED STORAGE	Room temperature, protect from light	MANUFACTURER	Not declared by client
VISUAL DESCRIPTION ON RECEIPT	Small clear glass vial · white lyophilised cake · white printed label intact · silver crimp · red flip cap · no visible particulates or discolouration		

CLIENT VIAL PHOTOGRAPH AS RECEIVED

SCOPE OF THIS CERTIFICATE

Included. Identity and composition by FTIR, peptide purity and potency by reversed-phase HPLC, peptide-to-excipient ratio, sterility screening and bacterial endotoxin by LAL, on the unit or units identified above. **Not included.** Elemental impurities, residual solvents, particulate matter, water content and container-closure integrity were not ordered and are not reported. **Results relate only to the sample as received** and to the lot identified above. This certificate is issued for research and quality-control purposes and is not a clearance for human or veterinary administration.

TEST RESULTS

TEST	METHOD	SPECIFICATION	RESULT	STATUS
IDENTITY, PURITY & POTENCY				
General appearance	Visual examination	White lyophilised powder	Conforms	PASS
Mass as received	Gravimetric	As recorded	156.0 mg	RECORDED
Identity & composition	FTIR, comparison to reference spectrum	Spectrum confirms the target peptide	Confirmed	PASS
Peptide purity	RP-HPLC, USP <621>, area normalisation	≥ 98.0 %	99.13 %	PASS
Potency, net peptide content	RP-HPLC, USP <621>, external standard	90 – 110 % of 30 mg label	31.2 mg (104.0 %)	PASS
Peptide-to-excipient ratio	Calculated from mass and potency	1:2 to 1:10 typical for this format	1 : 4.0	REPORTED
MICROBIOLOGICAL & SAFETY				
Sterility screening	Microbial contamination screen	No growth	No growth	PASS
Bacterial endotoxin	Limulus amebocyte lysate, quantitative	No client limit declared — report only	0.04 EU/mL	REPORTED

AUTHORISED BY

Name of analytical reviewer
Registered Chemist · Analytical Reviewer
Peptology Analytical
PRC Lic. No. 0000000

Name of laboratory director
MD · Laboratory Director
Countersignature, optional service
PRC Lic. No. 0000000

Name of pharmacist
Registered Pharmacist
Countersignature, optional service
PRC Lic. No. 0000000

IDENTITY & COMPOSITION

FTIR identification and composition analysis

Retatrutide · Lot SPEC-2026-0001 · 1800 to 800 cm⁻¹ · absorbance mode



Amide I and II bands at 1700 to 1500 cm⁻¹ are consistent with the reference standard. Bands at 1140 to 860 cm⁻¹ correspond to the excipient present in the formulation.

PURITY & POTENCY

RP-HPLC purity and potency assay

Representative chromatogram · vial V0 · closest to batch mean purity



Main peak at 7.412 min, area 1,286.4 mAU·s. Purity is the target peptide as a percentage of all peptide-related peaks. See methodology below.

BATCH CONFORMITY — TWO VIALS ANALYSED FROM THE SAME LOT

VIAL	PURITY	POTENCY	IDENTITY	ENDOTOXIN	RESULT
V0 · primary ★ representative sample	99.13 %	31.2 mg	Confirmed	0.03 EU/mL	PASS
V1 · conformity	98.87 %	30.6 mg	Confirmed	0.05 EU/mL	PASS

PEPTIDE PURITY
99.00 %
mean · SD 0.18 % · n = 2

NET PEPTIDE CONTENT
30.9 mg
mean · SD 0.42 mg · n = 2

BACTERIAL ENDOTOXIN
0.04 EU/mL
mean · SD 0.014 EU/mL · n = 2

NOTES & METHODOLOGY

HOW TO READ THIS CERTIFICATE

Identity. Confirmed by FTIR comparison of the sample spectrum against a reference spectrum for the declared peptide, with the composition assessed for the presence of excipients or bulking agents.
Purity. Reversed-phase HPLC with area normalisation per USP <621>, at the detection wavelength of the laboratory's validated method for this compound. The value is the percentage of the target peptide relative to all peptide-related peaks. Non-peptide process impurities are excluded and are noted individually if above the reporting threshold.
Potency. Net peptide content quantified against an external reference standard and reported in mg per vial, excluding water, salts and counterions. The percentage shown is relative to the content declared on the client's label, not to the mass of powder in the vial.
Endotoxin. Reported as a quantitative value. Acceptable limits vary by product, matrix and intended route, so no universal pass or fail threshold is applied. Where a client declares an acceptance limit in writing, that limit appears in the specification column and a judgement is made against it.
Conformity. Each vial is analysed independently and in full. The representative sample marked ★ is the vial closest to the batch mean purity, and the chromatogram above is that vial.
Scope. Analysis was performed by Peptology Analytical's contracted analytical partner. Peptology Analytical is the submitting agent, exporter of record and certifying party. Results relate only to the sample as received. Retained material is consumed or destroyed to the laboratory's standard schedule and is not returned.

Anyone can verify this certificate

Scan the code, or go to **peptology.ph/verify** and enter certificate **PEP-COA-2026-SPEC-0001** with access code **K7M2QX**. The page shows the issue date, lot, tests performed and results, and flags any certificate that has been superseded or withdrawn.